

WO 02/060507

1/10

PCT/NL02/00065




Fig. 1

WO 02/060507

2/10

PCT/NL02/00065




Fig. 2

WO 02/060507

3/10

PCT/NL02/00065





Fig. 3

WO 02/060507

4/10

PCT/NL02/00065

Figure 4: Dissolution of biomimetic calcium phosphate coating in saline solution at pH 7.3 at 37°C. Calcium release as function of immersion time.




WO 02/060507

5/10

PCT/NL02/00065

Figure 5: Growth factor release as function of immersion time in saline solution at pH 7.3 and 37°C.




WO 02/060507

6/10

PCT/NL02/00065

Figure 6: Molecular structure of tobramycin




WO 02/060507

7/10

PCT/NL02/00065

Figure 7: Incorporation of tobramycin in the biomimetic CHA coating by using co-precipitation




WO 02/060507

8/10

PCT/NL02/00065

Figure 8: Adsorption of tobramycin on plasma sprayed calcium phosphate coating in different concentrated solution for 10, 40 minutes or 48 hours




WO 02/060507

9/10

PCT/NL02/00065

Figure 9: Inhibition zone for *staphylococcus aureus* bacteria growth observed around a titanium disc coated with the biomimetic CHA coating produced with 250 mg/l tobramycin in solution



WO 02/060507

10/10

PCT/NL02/00065

Figure 10: Colony forming units (CFU) per gram of bone around titanium implants coated with apatite coatings without or with tobramycin after injection of 10^6 CFU of staphylococcus aureus in the bone defect and implantation for 4 weeks in NZW rabbits.

